Table 3.
Mutational status and metastatic recurrence
|
Metastatic recurrence |
Patients |
Test | |||||
|---|---|---|---|---|---|---|---|
|
No |
Yes |
||||||
| N=81 | N=17 | N=98 | |||||
|
KRAS mutation | |||||||
| Non |
63 |
(77.8%) |
12 |
(70.6%) |
75 |
(76.5%) |
|
| Yes |
18 |
(22.2%) |
5 |
(29.4%) |
23 |
(23.5%) |
|
|
BRAF mutation |
|
|
|
|
|
|
Fisher Exact P = 0.318 |
| Non |
80 |
(98.8%) |
16 |
(94.1%) |
96 |
(98.0%) |
|
| Yes |
1 |
(1.2%) |
1 |
(5.9%) |
2 |
(2.0%) |
|
|
PIK3CA mutation |
|
|
|
|
|
|
Fisher Exact P = 0.539 |
| Non |
78 |
(96.3%) |
16 |
(94.1%) |
94 |
(95.9%) |
|
| Yes |
3 |
(3.7%) |
1 |
(5.9%) |
4 |
(4.1%) |
|
|
All mutations |
|
|
|
|
|
|
|
| At least one mutation |
|
|
|
|
|
|
Fisher Exact P = 0.377 |
| No |
61 |
(75.3%) |
11 |
(64.7%) |
72 |
(73.5%) |
|
| Yes |
20 |
(24.7%) |
6 |
(35.3%) |
26 |
(26.5%) |
|
| Nb of mutations |
|
|
|
|
|
|
Fisher Exact P = 0.462 |
| 0 |
61 |
(75.3%) |
11 |
(64.7%) |
72 |
(73.5%) |
|
| 1 |
18 |
(22.2%) |
5 |
(29.4%) |
23 |
(23.5%) |
|
| 2 | 2 | (2.5%) | 1 | (5.9%) | 3 | (3.1%) | |